Investigators at St. Jude receive grants from the NIGMS for a Center for Precision Medicine in Leukemia to optimize curative treatments, translate genomics, and inform genomics methods for other disease treatments.
Evidence from the Childhood Cancer Survivor Study (CCSS) suggests that changes in childhood cancer treatment have reduced deaths from the late effects of cancer treatment and extended the lives of childhood cancer survivors. St. Jude Children’s Research Hospital investigators presented the research at the plenary session of the 2015 annual meeting of the American Society of Clinical Oncology (ASCO).
Researchers have identified three genes that play a pivotal role in the brain tumor choroid plexus carcinoma (CPC), a discovery that lays the groundwork for more effective treatment of this rare, often fatal cancer.
St. Jude Children’s Research Hospital scientists show that mutations in the DDX3X gene lead to different molecular defects; findings will aid efforts to develop more individualized therapy of medulloblastoma.
St. Jude Children’s Research Hospital study lays the foundation for more effective treatment of childhood leukemia and a wide range of other disorders using small molecules to reverse glucocorticoid resistance
Whole exome sequencing of 20 pediatric ALL patients yielded important insights into the genetic basis of ALL treatment failure. The findings may lead to early detection of the mutations that drive ALL relapse.
St. Jude Children’s Research Hospital scientists identify key molecular events in pediatric adrenocortical tumors; findings could help clinicians identify most malignant subtypes and lead to better treatment.
St. Jude Children’s Research Hospital—Washington University Pediatric Cancer Genome Project study highlights need for targeted therapies against a rare infant leukemia with a poor prognosis. (James R. Downing, MD)